Intetumumab
Product Specifications
UNSPSC Description
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer[1][2].
Target Antigen
EGFR
Type
Inhibitory Antibodies
Related Pathways
JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/intetumumab.html
Purity
99.24
Solubility
10 mM in DMSO
Smiles
[Intetumumab]
Molecular Weight
145.6 (kDa)
References & Citations
[1]Bellone M, et, al. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer. 2011 Aug;21(6):1084-90.|[2]Gonzalez-Nicolini V, et, al. Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy. Clin Cancer Res. 2016 May 15;22(10):2453-61.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99296/Intetumumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99296/Intetumumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
725735-28-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1339651-01 0.02 mg (E-Coli)
Recombinant Moritella profunda Argininosuccinate synthase (argG)
Ask
View Details 
MBS1339651-02 0.02 mg (Yeast)
Recombinant Moritella profunda Argininosuccinate synthase (argG)
Ask
View Details MBS1339651-03 0.1 mg (E-Coli)
Recombinant Moritella profunda Argininosuccinate synthase (argG)
Ask
View Details 
MBS1339651-04 0.1 mg (Yeast)
Recombinant Moritella profunda Argininosuccinate synthase (argG)
Ask
View Details